Novartis’ Tasigna Joins Bristol’s Sprycel For CML Resistant To Gleevec
Novartis expects Tasigna (nilotinib) will be used in the small number of chronic myeloid leukemia patients with advanced resistant disease who already have received high dose Gleevec (imatinib), and as a result, is pricing the product on par with the 800 mg dose of Gleevec typically used for such patients - about $5,700 per month
You may also be interested in...
Novartis is aiming to launch a trio of potential blockbuster oncology drugs in the next few years that the firm hopes will erase the memory of several recent high-profile setbacks in multiple therapeutic areas
Novartis is now facing a longer delay for its dipeptidyl peptidase-4 agent Galvus (vildagliptin) than previously predicted, since the safety study in patients with renal impairment requested by FDA will take at least six months, not "weeks" as originally suggested
The company plans to move PRA023 forward into Phase III studies based on positive Phase II safety and efficacy data in UC and Crohn's disease, positioning Prometheus in a race with Roivant.